Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats

Drug Metabolism and Disposition

Volumn 24, Issue 5, 1996, Pages 560-564

  Blotnik, Simcha ^a   Bergman, Felix ^a   Bialer, Meir ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; PRODRUG; UNCLASSIFIED DRUG; VALNOCTAMIDE; VALNOCTIC ACID; VALPROIC ACID; VALPROIC ACID DERIVATIVE; VALPROMIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ANXIETY; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG THERAPY; DRUG TRANSFORMATION; DRUG URINE LEVEL; EPILEPSY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT;

AMIDES; ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; BRAIN; LIVER; MALE; RATS; TISSUE DISTRIBUTION; VALPROIC ACID;

EID: 0029979326     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. M. Bialer Clinical pharmacology of valpromide. Clin. Pharmacokinet. 20, 114-122 (1991).
2. W. Stephansky: A clinical study on the use of valmethamide as anxiety-reducing drug. Curr. Ther. Res. 2, 144-149 (1960).
3. J. P. Chambon and A. Peiro: Valnoctamide: pharmacological data suggesting an antiepileptic activity. Neurosci. Lett. Suppl. S327-S327 (1980).
4. A. Haj-Yehia and M. Bialer Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity. Pharm. Res. 6, 682-689 (1989).
5. A. Haj-Yehia and M. Bialer: Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. J. Pharm. Sci. 77, 831-834 (1988).
6. A. Haj-Yehia and M. Bialer: Structure-pharmacokinetic relationships in a series of short chain fatty acid amides that possess anticonvulsant activity. J. Pharm. Sci. 79, 719-724 (1990).
7. M. Bialer, A. Haj-Yehia, N. Barzaghi, F. Pisani, and E. Perruca: Pharmacokinetics of valpromide isomer, valnoctamide, in healthy subjects. Eur. J. Clin. Pharmacol. 38, 289-291 (1990).
8. F. Pisani, A. Haj-Yehia, F. Fazio, C. Artesi, G. Oteri, E. Perucca, D. L. Koertz, R. H. Levy, and M. Bialer: Carbamazepine-valnoctamide interaction in epileptic patients: in vitro/in vivo correlation. Epilepsia 34, 954-959 (1993).
9. M. Bialer and A. Rubinstein: A comparative study on the pharmacokinetics of valpromide after intravenous administration in dogs. J. Pharm. Pharmacol. 35, 607-609 (1983).
10. M. Bialer and A. Rubinstein: Pharmacokinetics of valpromide in dogs after various modes of administration. Biopharm. Drug Dispos. 5, 177-183 (1984).
11. H. Billig, E. Ziv, H. Bar-On, and M. Bialer: The disposition of valpromide in rats and in the isolated perfused rat liver. Drug Metab. Dispos. 18, 238-244 (1990).
12. W. Loscher and H. Nau: Pharmacological evaluation of various metabolites and analogues of valproic acid. Neuropharmacology 24, 427-435 (1985).
13. H. Nau, R.-S. Huck, and K. Eblers: Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanism. Pharmacol. Toxicol. 69, 310-321 (1991).
14. M. Bialer, A. Rubinstein, J. Dubrovsky, I. Raz, and O Abramsky: A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans. Int. J. Pharm. 23, 25-33 (1985).
15. A. Haj-Yehia, S. Hadad, and M. Bialer: Pharmacokinetic analysis of the structural requirements for forming stable analogues of valpromide. Pharm. Res. 9, 1058-1063 (1992).
16. F. Monaco and G. Sechi: The brain distribution of old and new antiepileptic drugs. In "New Antiepileptic Drugs" (F. Pisani, E. Perucca, G. Avanzini, and A. Richens, eds.), pp. 57-65. Elsevier, Amsterdam, 1991.
17. H. G. Wieser: Comparison of valproate concentrations in human plasma, CSF and brain distribution after administration of different formulations of valproate and valpromide. Epilepsy Res. 9, 154-159 (1991).
18. L. J. Haberer and G. M. Pollack: Disposition and protein binding of valproic acid in the developing rat. Drug Metab. Dispos. 22, 113-119 (1994).
19. M. Bialer, M. Friedman, and A. Rubinstein: A rapid GLC assay for monitoring valproic acid and valpromide in plasma. J. Pharm. Sci. 73, 991-993 (1984).
20. M. Bialer and B. Hoch: Rapid gas chromatography assay for monitoring valnoctamide. J. Chromatogr. Biomed. Appl. 337, 408-411 (1985).
21. M. Gibaldi and D. Perrier: "Pharmacokinetics," 2nd ed., pp. 409-417. Marcel Dekker. New York, 1982.
22. M. Gibaldi and D. Perrier: "Pharmacokinetics," 2nd ed., pp. 409-417. Marcel Dekker, New York, 1982.
23. L. Z. Benet and R. L. Galeazzi: Non-compartmental determination of steady-state volume of distribution. J. Pharm. Sci. 68, 1071-1074 (1979).
24. K. Yamaoka, T. Nakagawa, and T. Uno: Statistical moment in pharmacokinetics. J. Pharmacokinet. Biopharm. 6, 547-588 (1978).
25. K. Yamaoka: "Methods for Pharmacokinetic Analysis for Personal Computer," 2nd ed., pp. 145-175. Nanko-D. Tokyo, 1986.
26. S. A. Kaplan, M. L. Jack, S. Cotler, and K. Alexander: Utilization of area under the curve to elucidate the disposition of extensively biotransformed drug. J. Pharmacokinet. Biopharm. 1, 201-216 (1973).
27. G. R. Wilkinson and D. G. Shand: A physiological approach to hepatic clearance. Clin. Pharmacol. Ther. 18, 377-389 (1975).
28. M. Rowland and T. Tozer: "Clinical Pharmacokinetics," 3rd ed., pp. 158-163. Williams & Wilkins, Baltimore, 1995.
29. P. L. Altman and D. S. Dittmer: "Biological Data Book," 2nd ed., vol. 3, pp. 1702-1710. Federation of American Societies for Experimental Biology, Bethesda, MD, 1974.
30. H. Nau and W. Loscher: Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and gamma-aminobutyric acid (GABA) metabolism in the mouse. J. Pharmacol. Exp. Ther. 220, 654-659 (1982).
31. E. J. Hammond, R. J. Perchalski, H. J. Villarreal, and B. J. Wilder: In vivo uptake of valproic acid in brain. Brain Res. 240, 195-198 (1982).
32. W. Loscher and H. Nau: Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment. J. Pharmacol. Exp. Ther. 226, 845-854 (1983).
33. R. Ichimura, Y. Deguchi, K. Yokogama, and T. Yamana: Physiologically based pharmacokinetics of valproic acid in rabbits. Int. J. Pharm. 27, 45-60 (1985).
34. J. S. Lockard, C. T. Viswanthan, and R. H. Levy: Diurnal oscillations of CFS valproate in monkey. Life Sci. 36, 1281-1285 (1985).
35. 2-valproate and valproate in rats. Epilepsia 32, 232-241 (1991).
36. F. J. E. Vajda, G. A. Donnan, J. Phillips, and P. F. Bladin: Human brain plasma and cerebrospinal fluid concentration of sodium valproate after 72 hours of therapy. Neurology 31, 486-487 (1981).
37. W. Loscher, H. Nau, and H. Siemes: Penetration of valproate and its active metabolites into cerebrospinal fluid of children with epilepsy. Epilepsia 29, 311-316 (1988).
38. D. D. Shen, G. A. Ojemann, R. L. Rapport, R. L. Dills, P. N. Friel, and R. H. Levy: Low and variable presence of valproic acid in human brain. Neurology 42, 582-585 (1992).
39. K. D. K. Adkison, A. A. Arturu, K. M. Powers, and D. D. Shen: Distribution of probenecid-sensitive anion transport processes at the brain capillary endothelium and choroid plexus to the efficient efflux of valproic acid from the central nervous system. J. Pharmacol. Exp. Ther. 268, 797-805 (1994).